Anebulo Pharmaceuticals is focused on developing innovative therapeutics to address acute cannabinoid toxicities, particularly unintentional cannabis poisoning and acute cannabinoid intoxication. Their lead investigational candidate, ANEB-001, is a cannabinoid antagonist designed to reverse the effects of cannabinoid intoxication. This small molecule is characterized as a competitive CB1 antagonist with a high affinity for the human CB1 receptor, which is crucial for mitigating the symptoms associated with cannabinoid exposure. The company has successfully completed Phase 2 clinical trials, demonstrating favorable tolerability and efficacy in rapidly reversing the effects of cannabinoid intoxication, particularly in scenarios involving THC.

The increasing legalization of cannabis across various states has led to a rise in emergency room visits due to cannabinoid intoxication, highlighting the urgent need for effective treatments. Anebulo aims to leverage distinct formulations of ANEB-001 to create multiple products targeting acute cannabis toxicities, thereby expediting the development process. The company is committed to addressing the unmet medical need for a specific antidote for cannabinoid intoxication, as there are currently no approved medical treatments available. Through their research and development efforts, Anebulo Pharmaceuticals seeks to improve the lives of patients affected by the growing incidence of cannabis-related emergencies.

United States

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Central Nervous System (CNS)

Anebulo Pharmaceuticals

Cannabinoid intoxication

<p class="font_7">ANEB-001 is a potent, small molecule cannabinoid receptor antagonist, &nbsp;to address the unmet medical need for a specific antidote for &nbsp;cannabinoid intoxication. We believe ANEB-001 will reverse the symptoms &nbsp;of cannabinoid intoxication within 1 hour of administration based on our &nbsp;Phase 1a and 1b data. We anticipate starting our first Phase 2 trial &nbsp;for ANEB-001 in 2021.</p>

Anebulo Pharmaceuticals

Company Details